Erasca (ERAS) Long-Term Investments (2021 - 2026)
Erasca (ERAS) reported Long-Term Investments of $164.7 million for Q1 2026, up 54.68% on a YoY basis from $106.5 million in Q1 2025, and up 150.63% quarter-over-quarter from $65.7 million in Q4 2025.
Erasca (ERAS) Long-Term Investments (2021 - 2026) Analysis & Trends
Erasca has reported Long-Term Investments for 6 years, with the latest figure at $164.7 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 54.68% year-over-year to $164.7 million; the trailing twelve-month figure through Mar 2026 stood at $164.7 million (up 54.68% YoY), and the FY2025 full-year result was $65.7 million, down 53.77% from the prior year.
- Long-Term Investments for Q1 2026 stood at $164.7 million, up from $65.7 million in the prior quarter.
- The five-year high for Long-Term Investments was $164.7 million in Q1 2026, with the low at $9.6 million in Q3 2022.
- Historically, Long-Term Investments has averaged $71.3 million across 5 years, with a median of $58.8 million in 2024.
- Annual changes were most pronounced in 2024 — Long-Term Investments soared 1374.42% — and 2025, when it slumped 53.77%.
- Erasca's Long-Term Investments stood at $9.6 million in 2022, then grew by 0.44% to $9.6 million in 2023, then soared by 1374.42% to $142.2 million in 2024, then tumbled by 53.77% to $65.7 million in 2025, then soared by 150.63% to $164.7 million in 2026.
- The last three Long-Term Investments figures came in at $164.7 million (Q1 2026), $65.7 million (Q4 2025), and $74.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 164.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164.72 Mn |
| Dec 31, 2025 | 65.72 Mn |
| Sep 30, 2025 | 73.98 Mn |
| Jun 30, 2025 | 86.09 Mn |
| Mar 31, 2025 | 106.49 Mn |
| Dec 31, 2024 | 142.16 Mn |
| Sep 30, 2024 | 144.40 Mn |
| Jun 30, 2024 | 51.80 Mn |
| Dec 31, 2023 | 9.64 Mn |
| Sep 30, 2023 | 46.90 Mn |
| Jun 30, 2023 | 48.08 Mn |
| Sep 30, 2022 | 9.60 Mn |
| Jun 30, 2022 | 19.30 Mn |
| Mar 31, 2022 | 29.22 Mn |
| Dec 31, 2021 | 44.77 Mn |
| Jun 30, 2021 | 5.00 Mn |